Micot Pharma

The supplied evidence does not describe Micot Pharma. The only source provided is a Chinese financial news article about Shaoneng Group (韶能股份, ticker 000601), a Guangdong-based clean-energy and precision-manufacturing company, and it contains no mention of Micot Pharma, its products, ownership, or history. Because no official-site or Wikipedia brand-sense evidence was supplied, this entry cannot responsibly describe Micot Pharma's origin, offerings, markets, or corporate structure. The name resembles a pharmaceutical trademark, but that is an inference from the name alone and is not supported by the evidence. This dossier is therefore flagged for review and kept deliberately short; it should be rebuilt once reliable brand sources (official website, company registry, or Wikipedia brand article) are available.

• 2026-10-04

  Micot Pharma debuts MT200605 Huntington's disease research in poster presentation at MDS 2026[2]Micot Pharma在MDS 2026以电子海报首次发布MT200605亨廷顿病研究finanznachrichten.de

  Reported: 2026-10-12

  Micot Pharma (2335.HK) presented for the first time, in an electronic poster at the MDS 2026 congress in Seoul, nonclinical findings in Huntington's disease and Phase I clinical results in healthy volunteers for its independently developed drug candidate MT200605, a small-molecule TrkB agonist. Together with previously announced positive Phase II data in acute ischemic stroke, the findings establish a development path for the candidate from acute brain injury into neurodegenerative diseases.

1. 1韶能股份前三季度归母净利预增61.12%至75.03%，北向资金持股创历史新高-财经-金融界finance.jrj.com.cn
2. 2Micot Pharma在MDS 2026以电子海报首次发布MT200605亨廷顿病研究finanznachrichten.de